## Auryon Atherectomy System Fast Facts

# THIS CHANGES EVERYTHING

The Auryon Atherectomy System and Auryon Atherectomy Catheters with aspiration are indicated for use as atherectomy
devices for arterial stenoses, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and
stented infra-inquinal arteries.

• The Auryon Atherectomy System and Auryon Atherectomy Catheters without aspiration are indicated for use in the treatment, including atherectomy, of infra-inquinal stenoses and occlusions.

 The Auryon System represents a technological breakthrough among medical devices used in atherectomy procedures to treat Peripheral Arterial Disease (PAD).

• The Auryon System's laser technology is the only system capable of delivering short, high-powered pulsed-laser energy.

 The Auryon System advances therapy options for PAD by treating all lesion types and calcification levels, both above- and below-the-knee. The technology is fast and effective, and shown in clinical studies to be effective in treating lesions ranging from soft plaque to severely calcified<sup>1, 2</sup>.

 The Auryon System utilizes a solid state laser delivery system that delivers an optimized wavelength, pulse width, and amplitude to remove calcified lesions while preserving vessel wall endothelium<sup>3, 4.</sup>

• The Auryon System's solid state laser produces a photon energy of 3.5 eV, which is low enough to be nonreactive to vessel endothelium, but high enough to vaporize calcium<sup>1,3</sup>. This technology has an affinity three times higher for lesion tissue versus vessel endothelium, giving providers the ability to ablate the lesion while preserving vessel endothelium<sup>3</sup>. Additionally, the Auryon System's targeted 355-nm wavelength does not react with contrast media, giving providers the ability to simultaneously ablate and observe fluoroscopy imaging<sup>5</sup>.

 When used to treat ISR during the Auryon System Pivotal trial, 0% target lesion revascularization (TLR) was shown at 6 months<sup>1,2</sup>.

 The Auryon System features aspiration in certain catheter sizes, reducing the risk of embolization<sup>1</sup>.

The solid state laser technology used in the Auryon System
uses no toxic gases, requires no calibration by staff, and requires minimal time for warm-up.

The 355 nm laser technology behind the Auryon System was developed by Eximo\* Medical, Ltd., and received 510(k) clearance from the FDA for use in the treatment of PAD. AngioDynamics acquired Eximo Medical and its laser technology platform in October 2019.





#### References

- Rundback, J, Chandra, P, Brodmann, M, et al. Catheter Cardiovasc Interv. 2019; 1- 8. https://doi.org/10.1002/ccd.28435
- Shammas NW, Chandra P, Brodmann M, et al. Acute and 30-Day Safety and Effectiveness Evaluation of Eximo Medical's B-Laser™, a Novel Atherectomy Device, in Subjects Affected With Infrainguinal Peripheral Arterial Disease: Results of the EX-PAD-03 Trial. Cardiovasc Revasc Med. 2020;21(1):86-92. doi:10.1016/j.carrev.2018.11.022
- Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287
- Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103(2):577-644
- Herzog A, Steinberg I, Gaisenberg E, Nomberg R, Ishaaya AA. A route to laser angioplasty in the presence of fluoroscopy contrast media, using a nanosecond-pulsed 355-nm laser. IEEE J Sel Top Quantum Electron. 2016;22(3):342-347.

#### Risk Information:

Caution: Federal (USA) law restricts the use of the system by or on the order of a physician.

Refer to Directions for Use and/or User Manual provided with the product for complete Instructions, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of the product.

#### Indications for Use:

The Auryon Atherectomy System and Auryon Atherectomy Catheters with aspiration are indicated for use as atherectomy devices for arterial stenoses, including in-stent restenosis (ISR), and to aspirate thrombus adjacent to stenoses in native and stented infra-inguinal arteries.

The Auryon Atherectomy System and Auryon Atherectomy Catheters without aspiration are indicated for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusions.



### angiodynamics

USA > 14 Plaza Drive, Latham, NY 12110 > tel: 800-772-6446 or 518-798-1215 > fax: 518-798-1360 International > Haaksbergweg 75 (Margriettoren), 1101 BR, Amsterdam Z-O > The Netherlands www.angiodynamics.com | Auryon-PAD.com

AngioDynamics, the AngioDynamics logo, Auryon, the Auryon logo, and Eximo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. © 2022 AngioDynamics, Inc. US/PA/MS/365 Rev 03 11/2022

